OncoMatch

OncoMatch/Clinical Trials/NCT06415669

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Is NCT06415669 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Paclitaxel for and Adebrelimab for gastric/gastroesophageal junction adenocarcinoma.

Phase 2RecruitingThe First Affiliated Hospital of Xiamen UniversityNCT06415669Data as of May 2026

Treatment: Paclitaxel for · Adebrelimab · Apatinib mesylateTo evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma following the progression of previous immunotherapy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Esophageal Carcinoma

Biomarker criteria

Excluded: HER2 (ERBB2) overexpression or amplification

HER2-positive patients [excluded]

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Max 2 prior lines
Min 1 prior line

Must have received: immunotherapy — first-line

Patients who have received at least first-line immunotherapy progression or intolerance in the past

Cannot have received: taxane (paclitaxel)

Exception: Neoadjuvant or adjuvant taxoid drugs allowed if disease progression >6 months after last chemotherapy

Patients who have previously received paclitaxel chemotherapy; Patients with neoadjuvant or adjuvant treatment with taxoid drugs and disease progression more than 6 months after the last chemotherapy were excluded

Lab requirements

Blood counts

ANC ≥1.5x10^9/L (no G-CSF in past 14 days); Platelets ≥100x10^9/L (no transfusion in past 14 days); Hemoglobin >90g/L (no transfusion or erythropoietin in past 14 days)

Kidney function

Serum creatinine ≤1.5× ULN and creatinine clearance ≥40 ml/min

Liver function

Total bilirubin ≤1.5× ULN; AST/ALT ≤2.5× ULN (≤5× ULN with liver metastasis)

Cardiac function

Myocardial enzyme profile within normal range (unless abnormality not clinically significant); Good coagulation function (INR or PT ≤1.5× ULN)

The major organs function normally and meet the following criteria...

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify